Organization
Brown University Warren Alpert Medical School
2 abstracts
Abstract
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.Org: Lantern Pharma, Mayo Clinic College of Medicine and Science, Scottsdale, AZ, Brown University Warren Alpert Medical School, Winship Cancer Institute of Emory University, DTC,
Abstract
GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.Org: Legorreta Cancer Center at Brown University, Providence, RI, Brown University - Lifespan Cancer Institute, NanoString Technologies, Inc., Seattle, WA,